Stock 688217 SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Rightongene Biotechnology Co., Ltd.

Equities

688217

CNE100005212

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
24.98 CNY +1.13% Intraday chart for Shanghai Rightongene Biotechnology Co., Ltd. -5.91% -30.18%
04-26 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-29 Shanghai Rightongene Biotechnology Co., Ltd. commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on February 28, 2024. CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • With an expected P/E ratio at 118.95 and 99.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD. Stock Shanghai Rightongene Biotechnology Co., Ltd.
-30.18% 193M -
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-1.52% 8.37B
B-
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+10.68% 5.96B
B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.94% 5.45B
C
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-5.09% 4.34B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-52.54% 3.18B
D+
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+14.18% 2.75B - -
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+32.50% 2.3B
C
VITROLIFE AB Stock Vitrolife AB
-6.47% 2.28B
B-
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-1.69% 1.92B
D+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 688217 Stock
  4. Ratings Shanghai Rightongene Biotechnology Co., Ltd.